Stockholm – November 15, 2024 – Inify Laboratories AB (publ), a unique laboratory service provider within pathology and cancer diagnostics, hereby invites its shareholders to Extraordinary General Meeting on December 6, 2024.
Please find attached the invitation including attachment, agenda and details on how to register and vote. The invitation is also available on the company’s website: www.inify.com.
For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: or: .
Attachment
View attachment
The future of pathology
Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses.
The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system.
The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.
This information is subject to the disclosure requirements pursuant to section 5–12 of the Norwegian Securities Trading Act.